The Indian pharma industry is now placing a major bet on biosimilars, which is hotting up after generics. With the expiration ...

The U.S. health-care system is at a crossroads. Generic drugs and biosimilars have the potential to reduce costs and improve access to life-saving treatments, but outdated policies and entrenched ...

The Association for Accessible Medicines’ annual U.S. Generic & Biosimilar Medicines Savings Report, in partnership with the IQVIA Institute, reveals that the use of Food and Drug Administration ...

Amneal Pharmaceuticals AMRX is leaning into a playbook that can work in multiple market backdrops. The company is pairing steady demand in generics with higher-value opportunities in complex ...

A new NITI Aayog report proposes "BioPharmaNext" and a ₹50,000-crore growth fund to transition India's pharmaceutical sector ...

According to the Association for Accessible Medicine’s 2024 U.S. Generic and Biosimilar Medicines Savings Report, the use of Food and Drug Administration-approved generic and biosimilar medicines ...

Indian pharma is entering its next growth phase as a new segment gains traction. We analyse four companies building this ...

How long before the biosimilar market looks like the generics market? While still a relatively new area of biopharma, the biosimilar market has been getting more and more competitive, with huge ...

Biologics are medications made using living organisms. Biosimilars are FDA-approved biologic products that are highly similar to an existing biologic (the reference drug). Biologic and biosimilar ...

Interchangeability impacts payer incentives, provider perceptions, and biosimilar adoption rates, with formulary status and complexity as barriers. Regulatory and legislative solutions are needed to ...

BENGALURU/HYDERABAD May 8 (Reuters) - Indian biopharma firm Biocon's (BION.NS), opens new tab profit more than doubled in the fourth quarter, led by strong demand for its generics and biosimilar drugs ...